Publication & Citation Trends
Publications
53 total
VP6-2022: Adjuvant pertuzumab and trastuzumab in patients with early HER-2 positive breast cancer in APHINITY: 8.4 years' follow-up PDF
Cited by 51
OpenAlex
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up PDF
Cited by 349
OpenAlex
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer PDF
Cited by 1,385
OpenAlex
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial PDF
Cited by 1,022
OpenAlex
Trastuzumab-Associated Cardiac Events at 8 Years of Median Follow-Up in the Herceptin Adjuvant Trial (BIG 1-01) PDF
Cited by 231
OpenAlex
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial
Cited by 501
OpenAlex
Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial
Cited by 611
OpenAlex
Research Topics
HER2/EGFR in Cancer Research
(43)
Breast Cancer Treatment Studies
(24)
Peptidase Inhibition and Analysis
(17)
Monoclonal and Polyclonal Antibodies Research
(12)
Cancer Treatment and Pharmacology
(11)
Affiliations
Roche (Switzerland)
Université Libre de Bruxelles
Institute of Cancer Research
Emory University
National and Kapodistrian University of Athens